Novo, Sanofi and Merck & Co all scored exits as the cancer drug developer, which had been spun off by Biox Biosciences, floated in a $101m offering.

Access Biotechnology is among the initial investors disclosed by Eliem Therapeutics, which is targeting neuronal excitability disorders.

The Finaves-backed developer of brain implant technology based on research from University of Manchester has secured series A funding.

The Novo-backed musculoskeletal disease therapy developer floated in an upsized IPO before its share price almost doubled on its first day of trading.

Bristol Myers Squibb has scored an exit from oncology therapy deveoper Ikena, whose share priced doubled on its first day of trading.

GV led the first disclosed round for the anti-viral nasal spray developer, investing $47.2m together with F-Prime Capital, Casdin Capital and Brook Byers.

Global Data Consortium, Guidefi, OfColor, Walnut and Zeta are the first startups to be chosen for FinRise, which targets underrepresented founders in tech.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The spinout of Yamaguchi University and National Cancer Centre Japan has raised the cash from investors including Dai-ichi Life and Binex.